Matthew Farrer

List of Publications by Citations

343 papers	29,855 citations	77 h-index	165 g-index
356 ext. papers	33,444 ext. citations	7.4 avg, IF	6.5 L-index

#	Paper	IF	Citations
343	alpha-Synuclein locus triplication causes Parkinson's disease. *Science*, **2003**, 302, 841	33.3	3252
342	Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron*, **2004**, 44, 601-7	13.9	2228
341	Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet, The*, **2004**, 364, 1167-9	40	1579
340	Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *New England Journal of Medicine*, **2009**, 361, 1651-61	59.2	1351
339	VPS35 mutations in Parkinson disease. *American Journal of Human Genetics*, **2011**, 89, 162-7	11	618
338	Genetics of Parkinson disease: paradigm shifts and future prospects. *Nature Reviews Genetics*, **2006**, 7, 306-18	30.1	567
337	Missing pieces in the Parkinson's disease puzzle. *Nature Medicine*, **2010**, 16, 653-61	50.5	521
336	Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. *Neuron*, **2002**, 36, 1007-19	13.9	506
335	alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. *Journal of Neuroscience*, **1999**, 19, 5782-91	6.6	469
334	Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. *American Journal of Human Genetics*, **2005**, 76, 672-80	11	453
333	Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. *Movement Disorders*, **2013**, 28, 811-3	7	433
332	High-resolution whole-genome association study of Parkinson disease. *American Journal of Human Genetics*, **2005**, 77, 685-93	11	433
331	Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. *PLoS Genetics*, **2012**, 8, e1002548	6	420
330	Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. *JAMA - Journal of the American Medical Association*, **2006**, 296, 661-70	27.4	403
329	LRRK2 in Parkinson's disease: protein domains and functional insights. *Trends in Neurosciences*, **2006**, 29, 286-93	13.3	390
328	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nature Genetics*, **2011**, 43, 699-705	36.3	386
327	Advances in the genetics of Parkinson disease. *Nature Reviews Neurology*, **2013**, 9, 445-54	15	353

326	A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. *Nature Medicine*, **1998**, 4, 452-5	50.5	302
325	Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. *Annals of Neurology*, **2006**, 59, 298-309	9.4	281
324	Molecular mapping of Alzheimer-type dementia in Down's syndrome. *Annals of Neurology*, **1998**, 43, 380-3	9.4	275
323	Genomic investigation of alpha-synuclein multiplication and parkinsonism. *Annals of Neurology*, **2008**, 63, 743-50	9.4	269
322	The genetics of Parkinson's disease: progress and therapeutic implications. *Movement Disorders*, **2013**, 28, 14-23	7	248
321	Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. *Neurobiology of Disease*, **2001**, 8, 535-9	7.5	242
320	DCTN1 mutations in Perry syndrome. *Nature Genetics*, **2009**, 41, 163-5	36.3	239
319	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. *Lancet Neurology, The*, **2011**, 10, 898-908	24.1	237
318	Lrrk2 and Lewy body disease. *Annals of Neurology*, **2006**, 59, 388-93	9.4	237
317	Translation initiator EIF4G1 mutations in familial Parkinson disease. *American Journal of Human Genetics*, **2011**, 89, 398-406	11	213
316	Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. *Neurobiology of Disease*, **2010**, 40, 503-17	7.5	210
315	DNAJC13 mutations in Parkinson disease. *Human Molecular Genetics*, **2014**, 23, 1794-801	5.6	209
314	PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. *Brain*, **2005**, 128, 2777-85	11.2	208
313	Lrrk2 pathogenic substitutions in Parkinson's disease. *Neurogenetics*, **2005**, 6, 171-7	3	207
312	Biochemical and pathological characterization of Lrrk2. *Annals of Neurology*, **2006**, 59, 315-22	9.4	205
311	alpha-Synuclein promoter confers susceptibility to Parkinson's disease. *Annals of Neurology*, **2004**, 56, 591-5	9.4	182
310	A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. *Human Molecular Genetics*, **1999**, 8, 81-5	5.6	177
309	Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. *Annals of Neurology*, **2008**, 64, 88-92	9.4	176

308	The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. *American Journal of Human Genetics*, **2004**, 74, 11-9	11	169
307	Clinical features of LRRK2-associated Parkinson's disease in central Norway. *Annals of Neurology*, **2005**, 57, 762-5	9.4	150
306	Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. *Parkinsonism and Related Disorders*, **2007**, 13, 89-92	3.6	148
305	Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. *Neurobiology of Disease*, **2011**, 41, 706-16	7.5	146
304	Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. *Neurobiology of Disease*, **2015**, 78, 172-95	7.5	140
303	LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. *Molecular Neurodegeneration*, **2012**, 7, 25	19	139
302	LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. *Lancet Neurology, The*, **2008**, 7, 591-4	24.1	136
301	Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. *PLoS Genetics*, **2011**, 7, e1002171	6	135
300	Dopamine transporter genetic variants and pesticides in Parkinson's disease. *Environmental Health Perspectives*, **2009**, 117, 964-9	8.4	135
299	Low frequency of alpha-synuclein mutations in familial Parkinson's disease. *Annals of Neurology*, **1998**, 43, 394-7	9.4	134
298	Functional alteration of PARL contributes to mitochondrial dysregulation in Parkinson's disease. *Human Molecular Genetics*, **2011**, 20, 1966-74	5.6	131
297	Linkage disequilibrium and association of MAPT H1 in Parkinson disease. *American Journal of Human Genetics*, **2004**, 75, 669-77	11	130
296	The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. *Neuroscience Letters*, **2005**, 384, 327-9	3.3	128
295	Parkin genetics: one model for Parkinson's disease. *Human Molecular Genetics*, **2004**, 13 Spec No 1, R127-33	5.6	128
294	Genetics and genomics of Parkinson's disease. *Genome Medicine*, **2014**, 6, 48	14.4	125
293	Parkin variants in North American Parkinson's disease: cases and controls. *Movement Disorders*, **2003**, 18, 1306-11	7	121
292	Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. *Archives of Neurology*, **2001**, 58, 296-9		117
291	Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. *Journal of Neurochemistry*, **2003**, 85, 957-68	6	116

290	LRRK2 and Parkinson disease. *Archives of Neurology*, **2010**, 67, 542-7		114
289	Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). *Movement Disorders*, **2004**, 19, 622-9	7	112
288	RING finger 1 mutations in Parkin produce altered localization of the protein. *Human Molecular Genetics*, **2003**, 12, 2957-65	5.6	111
287	Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. *Human Molecular Genetics*, **2003**, 12, 1223-31	5.6	110
286	Large-scale replication and heterogeneity in Parkinson disease genetic loci. *Neurology*, **2012**, 79, 659-67	6.5	106
285	LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. *Neurogenetics*, **2010**, 11, 401-8	3	106
284	Expanding the clinical phenotype of SNCA duplication carriers. *Movement Disorders*, **2009**, 24, 1811-9	7	103
283	Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. *PLoS ONE*, **2010**, 5, e12122	3.7	101
282	Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. *Neuroscience*, **2006**, 139, 791-4	3.9	100
281	Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N. *Human Molecular Genetics*, **2015**, 24, 1691-703	5.6	98
280	Identification of a novel gene linked to parkin via a bi-directional promoter. *Journal of Molecular Biology*, **2003**, 326, 11-9	6.5	98
279	Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. *Movement Disorders*, **2006**, 21, 1102-8	7	96
278	A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. *Neuroscience*, **2007**, 147, 1047-58	3.9	96
277	Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. *American Journal of Human Genetics*, **2001**, 68, 617-26	11	93
276	Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. *Brain*, **2017**, 140, 98-117	11.2	88
275	SCA2 may present as levodopa-responsive parkinsonism. *Movement Disorders*, **2003**, 18, 425-9	7	88
274	Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. *Movement Disorders*, **2010**, 25, 2156-63	7	86
273	In vivo silencing of alpha-synuclein using naked siRNA. *Molecular Neurodegeneration*, **2008**, 3, 19	19	86

272	Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. *Movement Disorders*, **2010**, 25, 2717-23	7	82
271	Functional association of the parkin gene promoter with idiopathic Parkinson's disease. *Human Molecular Genetics*, **2002**, 11, 2787-92	5.6	81
270	Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. *Human Mutation*, **2011**, 32, 1390-7	4.7	80
269	LRRK2 R1441G in Spanish patients with Parkinson's disease. *Neuroscience Letters*, **2005**, 382, 309-11	3.3	80
268	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. *Journal of Medical Genetics*, **2012**, 49, 721-6	5.8	78
267	LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. *Trends in Molecular Medicine*, **2006**, 12, 76-82	11.5	78
266	A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. *Parkinsonism and Related Disorders*, **2009**, 15, 627-32	3.6	77
265	Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. *Annals of Neurology*, **2011**, 69, 778-92	9.4	76
264	Localization of frontotemporal dementia with parkinsonism in an Australian kindred to chromosome 17q21-22. *Annals of Neurology*, **1997**, 42, 794-8	9.4	76
263	Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. *Archives of Neurology*, **2006**, 63, 1250-4		75
262	Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. *Archives of Neurology*, **2005**, 62, 82-7		75
261	Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. *Frontiers in Cellular Neuroscience*, **2014**, 8, 301	6.1	72
260	Pallidonigral TDP-43 pathology in Perry syndrome. *Parkinsonism and Related Disorders*, **2009**, 15, 281-6	3.6	72
259	Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. *Journal of Neurochemistry*, **2000**, 75, 2546-54	6	71
258	LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. *Human Molecular Genetics*, **2015**, 24, 1336-49	5.6	70
257	A comparative study of Lrrk2 function in primary neuronal cultures. *Parkinsonism and Related Disorders*, **2010**, 16, 650-5	3.6	68
256	Parkinson's disease: a rethink of rodent models. *Experimental Brain Research*, **2006**, 173, 196-204	2.3	68
255	LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. *Acta Neuropathologica*, **2013**, 126, 809-27	14.3	67

254	The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. *Neuroscience Letters*, **1999**, 270, 1-4	3.3	67
253	Disease penetrance of late-onset parkinsonism: a meta-analysis. *JAMA Neurology*, **2014**, 71, 1535-9	17.2	65
252	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. *Lancet Neurology, The*, **2017**, 16, 351-359	24.1	64
251	Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. *Neurobiology of Aging*, **2014**, 35, 1125-31	5.6	64
250	□synuclein genetic variability: A biomarker for dementia in Parkinson disease. *Annals of Neurology*, **2016**, 79, 991-9	9.4	64
249	Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. *Acta Neurologica Scandinavica*, **2008**, 118, 320-7	3.8	63
248	Identification of potential protein interactors of Lrrk2. *Parkinsonism and Related Disorders*, **2007**, 13, 382-5	3.6	61
247	Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. *American Journal of Human Genetics*, **2007**, 80, 769-78	11	61
246	Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. *Neurology*, **2020**, 94, 481-494	6.5	60
245	Loss-of-Function and Gain-of-Function Mutations in KCNQ5 Cause Intellectual Disability or Epileptic Encephalopathy. *American Journal of Human Genetics*, **2017**, 101, 65-74	11	58
244	LINGO1 rs9652490 is associated with essential tremor and Parkinson disease. *Parkinsonism and Related Disorders*, **2010**, 16, 109-11	3.6	58
243	MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. *Journal of Neuroscience Research*, **2007**, 85, 1288-94	4.4	57
242	Genetic variation of Omi/HtrA2 and Parkinson's disease. *Parkinsonism and Related Disorders*, **2008**, 14, 539-43	3.6	53
241	Transfected synphilin-1 forms cytoplasmic inclusions in HEK293 cells. *Molecular Brain Research*, **2001**, 97, 94-102		53
240	□Synuclein gene may interact with environmental factors in increasing risk of Parkinson's disease. *Neuroepidemiology*, **2010**, 35, 191-5	5.4	52
239	Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. *Neurobiology of Aging*, **2017**, 57, 248.e7-248.e12	5.6	51
238	Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. *Mechanisms of Ageing and Development*, **2007**, 128, 378-82	5.6	51
237	A genetic risk factor for periodic limb movements in sleep. *New England Journal of Medicine*, **2008**, 358, 425-7	59.2	50

236	Genomewide association, Parkinson disease, and PARK10. *American Journal of Human Genetics*, **2006**, 78, 1084-8; author reply 1092-4	11	50
235	DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study. *Lancet Neurology, The*, **2016**, 15, 1248-1256	24.1	50
234	Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. *Archives of Neurology*, **2010**, 67, 970-5		49
233	Case-Control study of the extended tau gene haplotype in Parkinson's disease. *Annals of Neurology*, **2001**, 50, 658-61	9.4	48
232	Defining neurodegeneration on Guam by targeted genomic sequencing. *Annals of Neurology*, **2015**, 77, 458-68	9.4	47
231	It's a double knock-out! The quaking mouse is a spontaneous deletion of parkin and parkin co-regulated gene (PACRG). *Movement Disorders*, **2004**, 19, 101-4	7	47
230	FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy. *Archives of Neurology*, **2005**, 62, 962-6		47
229	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. *Autophagy*, **2018**, 14, 1404-1418	10.2	47
228	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. *Neurobiology of Aging*, **2011**, 32, 548.e9-18	5.6	46
227	An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 424-9	5.5	46
226	Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. *Neuroscience Letters*, **2006**, 410, 80-4	3.3	46
225	LRRK2 mutations are a common cause of Parkinson's disease in Spain. *European Journal of Neurology*, **2006**, 13, 391-4	6	46
224	Genetic variation in the COL6A1 region is associated with congenital heart defects in trisomy 21 (Down's syndrome). *Annals of Human Genetics*, **1995**, 59, 253-69	2.2	46
223	A Meta-Analysis of ⊟Synuclein Multiplication in Familial Parkinsonism. *Frontiers in Neurology*, **2018**, 9, 1021	4.1	46
222	Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease. *Lancet Neurology, The*, **2015**, 14, 1054-64	24.1	45
221	Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. *Acta Neuropathologica*, **2007**, 113, 601-6	14.3	45
220	Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice. *ELife*, **2017**, 6,	8.9	44
219	Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. *Parkinsonism and Related Disorders*, **2008**, 14, 465-70	3.6	44

218	Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. *Annals of Neurology*, **2005**, 57, 439-43	9.4	43
217	Parkinsonism, FXTAS, and FMR1 premutations. *Movement Disorders*, **2005**, 20, 230-3	7	43
216	Diagnostic Yield and Treatment Impact of Targeted Exome Sequencing in Early-Onset Epilepsy. *Frontiers in Neurology*, **2019**, 10, 434	4.1	42
215	Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. *Movement Disorders*, **2002**, 17, 670-5	7	42
214	Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. *European Journal of Human Genetics*, **2001**, 9, 659-66	5.3	42
213	Association of the MAPT locus with Parkinson's disease. *European Journal of Neurology*, **2010**, 17, 483-6	6	41
212	The ups and downs of alpha-synuclein mRNA expression. *Movement Disorders*, **2007**, 22, 293-5	7	41
211	Phenotypic associations of tau and ApoE in Parkinson's disease. *Neuroscience Letters*, **2007**, 414, 141-4	3.3	41
210	Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease. *Movement Disorders*, **2002**, 17, 1305-11	7	41
209	Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease. *Movement Disorders*, **2000**, 15, 714-9	7	41
208	LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. *Journal of Biomedical Science*, **2008**, 15, 661-7	13.3	40
207	Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. *Parkinsonism and Related Disorders*, **2007**, 13, 509-15	3.6	39
206	Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice. *Npj Parkinson's Disease*, **2018**, 4, 27	9.7	38
205	DNAJC12 and dopa-responsive nonprogressive parkinsonism. *Annals of Neurology*, **2017**, 82, 640-646	9.4	38
204	FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. *Movement Disorders*, **2009**, 24, 455-9	7	38
203	Genome-wide analysis of the parkinsonism-dementia complex of Guam. *Archives of Neurology*, **2004**, 61, 1889-97		38
202	N-myc regulates parkin expression. *Journal of Biological Chemistry*, **2004**, 279, 28896-902	5.4	38
201	Variants in saposin D domain of prosaposin gene linked to Parkinson's disease. *Brain*, **2020**, 143, 1190-1205	10.2	37

200	De Novo Mutations in YWHAG Cause Early-Onset Epilepsy. *American Journal of Human Genetics*, **2017**, 101, 300-310	11	37
199	Glucocerebrosidase mutations in diffuse Lewy body disease. *Parkinsonism and Related Disorders*, **2011**, 17, 55-7	3.6	37
198	Leucine-rich repeat kinase 2 (LRRK2) regulates synuclein clearance in microglia. *BMC Neuroscience* , **2016**, 17, 77	3.2	37
197	Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease. *Journal of Medical Genetics*, **2004**, 41, 900-7	5.8	36
196	Elucidating the genetics and pathology of Perry syndrome. *Journal of the Neurological Sciences*, **2010**, 289, 149-54	3.2	35
195	Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson's disease. *Biochemical Society Transactions*, **2005**, 33, 586-90	5.1	35
194	Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3activity. *Human Molecular Genetics*, **2016**, 25, 1965-1978	5.6	34
193	LRRK2 exonic variants and risk of multiple system atrophy. *Neurology*, **2014**, 83, 2256-61	6.5	34
192	Reply to: SNCA variants are associated with increased risk of multiple system atrophy. *Annals of Neurology*, **2010**, 67, 414-5	9.4	34
191	Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. *Neurogenetics*, **2007**, 8, 95-102	3	34
190	A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 391-5	5.5	33
189	DNAJC13 genetic variants in parkinsonism. *Movement Disorders*, **2015**, 30, 273-8	7	32
188	LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. *Neurology*, **2014**, 83, 568-9	6.5	32
187	Glucosidase-beta variations and Lewy body disorders. *Parkinsonism and Related Disorders*, **2009**, 15, 414-6	3.6	32
186	Does synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?. *Parkinsonism and Related Disorders*, **2014**, 20, 584-9; discussion 584	3.6	31
185	Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. *Parkinsonism and Related Disorders*, **2012**, 18, 243-6	3.6	31
184	First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation. *Parkinsonism and Related Disorders*, **2012**, 18, 332-8	3.6	31
183	SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. *European Journal of Neurology*, **2011**, 18, 876-81	6	31

182	Evaluation of gastric emptying in familial and sporadic Parkinson disease. *Parkinsonism and Related Disorders*, **2009**, 15, 692-6	3.6	31
181	Lrrk2 R1441 substitution and progressive supranuclear palsy. *Neuropathology and Applied Neurobiology*, **2006**, 32, 23-5	5.2	31
180	Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release. *Parkinsonism and Related Disorders*, **2015**, 21, 1156-63	3.6	30
179	A novel DCTN1 mutation with late-onset parkinsonism and frontotemporal atrophy. *Movement Disorders*, **2014**, 29, 1201-4	7	30
178	Subclinical signs in LRRK2 mutation carriers. *Parkinsonism and Related Disorders*, **2011**, 17, 528-32	3.6	30
177	ATP13A2 variability in Parkinson disease. *Human Mutation*, **2009**, 30, 406-10	4.7	30
176	RAPIDOMICS: rapid genome-wide sequencing in a neonatal intensive care unit-successes and challenges. *European Journal of Pediatrics*, **2019**, 178, 1207-1218	4.1	29
175	The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease. *Movement Disorders*, **2018**, 33, 196-207	7	29
174	Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease. *Parkinsonism and Related Disorders*, **2010**, 16, 686-7	3.6	29
173	Common variants in PARK loci and related genes and Parkinson's disease. *Movement Disorders*, **2011**, 26, 280-8	7	28
172	Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. *Parkinsonism and Related Disorders*, **2009**, 15, 466-7	3.6	28
171	LRRK2 mutations and Parkinsonism. *Lancet, The*, **2005**, 365, 1229-30	40	28
170	Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. *Journal of Parkinson's Disease*, **2014**, 4, 483-98	5.3	27
169	Clinical and genetic features of families with frontotemporal dementia and parkinsonism linked to chromosome 17 with a P301S tau mutation. *Journal of Neural Transmission*, **2007**, 114, 947-50	4.3	27
168	Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy. *Parkinsonism and Related Disorders*, **2007**, 13, 340-2	3.6	27
167	The effect of tau genotype on clinical features in FTDP-17. *Parkinsonism and Related Disorders*, **2005**, 11, 205-8	3.6	27
166	LRRK2 mutations are not common in Alzheimer's disease. *Mechanisms of Ageing and Development*, **2005**, 126, 1201-5	5.6	27
165	The genetics of disorders with synuclein pathology and parkinsonism. *Human Molecular Genetics*, **1999**, 8, 1901-5	5.6	27

164	Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. *Neurobiology of Aging*, **2014**, 35, 266.e5-14	5.6	26
163	Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. *Parkinsonism and Related Disorders*, **2009**, 15, 539-41	3.6	26
162	Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases. *Neurobiology of Disease*, **2007**, 27, 238-47	7.5	26
161	Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. *Parkinsonism and Related Disorders*, **2005**, 11, 349-52	3.6	26
160	Clinical heterogeneity of the LRRK2 G2019S mutation. *Archives of Neurology*, **2006**, 63, 1242-6		26
159	Lack of mutations in DJ-1 in a cohort of Taiwanese ethnic Chinese with early-onset parkinsonism. *Movement Disorders*, **2004**, 19, 1065-9	7	26
158	Establishing diagnostic criteria for Perry syndrome. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 482-487	5.5	26
157	A family with Parkinsonism, essential tremor, restless legs syndrome, and depression. *Neurology*, **2011**, 76, 1623-30	6.5	25
156	Alpha-synuclein multiplications with parkinsonism, dementia or progressive myoclonus?. *Parkinsonism and Related Disorders*, **2009**, 15, 390-2	3.6	25
155	UCHL1 is associated with Parkinson's disease: a case-unaffected sibling and case-unrelated control study. *Neuroscience Letters*, **2005**, 381, 131-4	3.3	25
154	Complex interactions in Parkinson's disease: a two-phased approach. *Movement Disorders*, **2003**, 18, 631-6	7	25
153	Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for Parkinson's disease. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2005**, 136B, 72-4	3.5	25
152	Identification and characterization of the human parkin gene promoter. *Journal of Neurochemistry*, **2001**, 78, 1146-52	6	25
151	No pathogenic mutations in the beta-synuclein gene in Parkinson's disease. *Neuroscience Letters*, **1999**, 269, 107-9	3.3	25
150	Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease. *Parkinsonism and Related Disorders*, **2018**, 47, 39-44	3.6	25
149	Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. *Movement Disorders*, **2013**, 28, 1740-4	7	24
148	Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study. *Movement Disorders*, **2015**, 30, 253-8	7	24
147	Reported mutations in GIGYF2 are not a common cause of Parkinson's disease. *Movement Disorders*, **2009**, 24, 619-20	7	24

146	Fine-mapping and candidate gene investigation within the PARK10 locus. *European Journal of Human Genetics*, **2009**, 17, 336-43	5.3	24
145	Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. *Movement Disorders*, **2003**, 18, 758-63	7	24
144	The SON gene encodes a conserved DNA binding protein mapping to human chromosome 21. *Annals of Human Genetics*, **1994**, 58, 25-34	2.2	24
143	DCTN1 p.K56R in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2016**, 28, 56-61	3.6	24
142	A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in. *Case Reports in Neurological Medicine*, **2018**, 2018, 6838965	0.7	24
141	Identification of FUS p.R377W in essential tremor. *European Journal of Neurology*, **2014**, 21, 361-3	6	23
140	Parkinson-related genetics in patients treated with deep brain stimulation. *Acta Neurologica Scandinavica*, **2011**, 123, 201-6	3.8	23
139	Clinical findings in a large family with a parkin ex3delta40 mutation. *Archives of Neurology*, **2004**, 61, 701-4		23
138	Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease. *Neuroscience Letters*, **2004**, 367, 97-100	3.3	23
137	Autonomic failures in Perry syndrome with DCTN1 mutation. *Parkinsonism and Related Disorders*, **2010**, 16, 612-4	3.6	22
136	Genotype-phenotype correlates in Taiwanese patients with early-onset recessive Parkinsonism. *Movement Disorders*, **2009**, 24, 104-8	7	22
135	Sporadic SCA8 mutation resembling corticobasal degeneration. *Parkinsonism and Related Disorders*, **2005**, 11, 147-50	3.6	22
134	Heterotrisomy, a significant contributing factor to ventricular septal defect associated with Down syndrome?. *Human Genetics*, **2000**, 107, 476-82	6.3	22
133	Gender differences in Parkinson's disease depression. *Parkinsonism and Related Disorders*, **2017**, 36, 93-97	3.6	21
132	[11C]PBR28 PET imaging is sensitive to neuroinflammation in the aged rat. *Journal of Cerebral Blood Flow and Metabolism*, **2015**, 35, 1331-8	7.3	21
131	In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 59-66	7.3	21
130	Clinical and Genetic Description of a Family With a High Prevalence of Autosomal Dominant Restless Legs Syndrome. *Mayo Clinic Proceedings*, **2009**, 84, 134-138	6.4	21
129	PARK11 is not linked with Parkinson's disease in European families. *European Journal of Human Genetics*, **2005**, 13, 193-7	5.3	21

128	Tau neurotoxicity without the lesions: a fly challenges a tangled web. *Trends in Neurosciences*, **2002**, 25, 327-9	13.3	21
127	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. *Movement Disorders*, **2020**, 35, 1755-1764	7	21
126	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. *Neurology*, **2015**, 85, 1283-92	6.5	20
125	Genetic variability of the retromer cargo recognition complex in parkinsonism. *Movement Disorders*, **2015**, 30, 580-4	7	20
124	Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. *Neuroscience Letters*, **2007**, 416, 299-301	3.3	20
123	ELAVL4, PARK10, and the Celts. *Movement Disorders*, **2007**, 22, 585-7	7	19
122	Genetic association studies in Alzheimer's disease research: challenges and opportunities. *Statistics in Medicine*, **2004**, 23, 169-78	2.3	19
121	De novo mutation in 2 patients with neonatal-onset epilepsy. *Neurology: Genetics*, **2016**, 2, e120	3.8	18
120	Histamine N-methyltransferase Thr105Ile is not associated with Parkinson's disease or essential tremor. *Parkinsonism and Related Disorders*, **2010**, 16, 112-4	3.6	18
119	Allelic variability in D21S11, but not in APP or APOE, is associated with cognitive decline in Down syndrome. *NeuroReport*, **1997**, 8, 1645-9	1.7	18
118	Beta-synuclein gene variants and Parkinson's disease: a preliminary case-control study. *Neuroscience Letters*, **2007**, 420, 229-34	3.3	18
117	The human sideroflexin 5 (SFXN5) gene: sequence, expression analysis and exclusion as a candidate for PARK3. *Gene*, **2002**, 285, 229-37	3.8	18
116	Parkinsonism in GTP cyclohydrolase 1 mutation carriers. *Brain*, **2015**, 138, e349	11.2	17
115	Mitochondrial translation initiation factor 3 polymorphism and Parkinson's disease. *Neuroscience Letters*, **2010**, 486, 228-30	3.3	17
114	Lrrk2 mutations in South America: A study of Chilean Parkinson's disease. *Neuroscience Letters*, **2007**, 422, 193-7	3.3	17
113	Parkinson's genetics: molecular insights for the new millennium. *NeuroToxicology*, **2002**, 23, 503-14	4.4	17
112	Genetic analysis of synphilin-1 in familial Parkinson's disease. *Neurobiology of Disease*, **2001**, 8, 317-23	7.5	17
111	Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. *Acta Neuropathologica*, **2013**, 125, 425-38	14.3	16

110	Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. *Neuroscience Letters*, **2010**, 477, 57-60	3.3	16
109	Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease. *Mechanisms of Ageing and Development*, **2010**, 131, 210-4	5.6	16
108	Phenotypic commonalities in familial and sporadic Parkinson disease. *Archives of Neurology*, **2006**, 63, 579-83		16
107	Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy. *Brain*, **2020**, 143, 3352-3373	11.2	16
106	Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. *Movement Disorders*, **2014**, 29, 1684-7	7	15
105	DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. *European Journal of Neurology*, **2015**, 22, 1323-5	6	15
104	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. *Neurobiology of Aging*, **2011**, 32, 2108.e1-5	5.6	15
103	Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population. *Movement Disorders*, **2009**, 24, 2411-4	7	15
102	Parkin is not regulated by the unfolded protein response in human neuroblastoma cells. *Neuroscience Letters*, **2003**, 341, 139-42	3.3	15
101	Accurate determination of ataxin-2 polyglutamine expansion in patients with intermediate-range repeats. *Genetic Testing and Molecular Biomarkers*, **2002**, 6, 217-20		15
100	STX6 rs1411478 is not associated with increased risk of Parkinson's disease. *Parkinsonism and Related Disorders*, **2013**, 19, 563-5	3.6	14
99	Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. *EJNMMI Research*, **2013**, 3, 69	3.6	14
98	GCH1 in early-onset Parkinson's disease. *Movement Disorders*, **2009**, 24, 2070-5	7	14
97	Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel. *Journal of Neural Transmission*, **2008**, 115, 1279-84	4.3	14
96	Dynamic control of the dopamine transporter in neurotransmission and homeostasis. *Npj Parkinson's Disease*, **2021**, 7, 22	9.7	14
95	Genetic Identification in Early Onset Parkinsonism among Norwegian Patients. *Movement Disorders Clinical Practice*, **2017**, 4, 499-508	2.2	13
94	Assessing an Interactive Online Tool to Support Parents' Genomic Testing Decisions. *Journal of Genetic Counseling*, **2018**, 28, 10	2.5	13
93	Familial aggregation of Parkinson's disease in the Faroe Islands. *Movement Disorders*, **2015**, 30, 538-44	7	13

92	Genealogical studies in LRRK2-associated Parkinson's disease in central Norway. *Parkinsonism and Related Disorders*, **2010**, 16, 527-30	3.6	13
91	Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson's disease from North Africa. *Movement Disorders*, **2010**, 25, 2052-8	7	13
90	Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations. *Movement Disorders*, **2004**, 19, 677-81	7	13
89	Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease. *Movement Disorders*, **2002**, 17, 509-12	7	13
88	Case-control study of the alpha-synuclein interacting protein gene and Parkinson's disease. *Movement Disorders*, **2003**, 18, 1233-9	7	13
87	No pathogenic mutations in the persyn gene in Parkinson's disease. *Neuroscience Letters*, **1999**, 259, 65-6	3.3	13
86	Polymorphisms and linkage disequilibrium in the COL6A1 and COL6A2 gene cluster: novel DNA polymorphisms in the region of a candidate gene for congenital heart defects in Down's syndrome. *Human Genetics*, **1993**, 90, 521-5	6.3	13
85	An Infant With Epilepsy and Recurrent Hemiplegia due to Compound Heterozygous Variants in ATP1A2. *Pediatric Neurology*, **2017**, 75, 87-90	2.9	12
84	Head injury, □synuclein genetic variability and Parkinson's disease. *European Journal of Neurology*, **2015**, 22, 874-8	6	12
83	In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. *Movement Disorders*, **2014**, 29, 1197-201	7	12
82	Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America. *Parkinsonism and Related Disorders*, **2011**, 17, 629-31	3.6	12
81	Genetic variants of □synuclein are not associated with essential tremor. *Movement Disorders*, **2011**, 26, 2552-6	7	12
80	Phactr2 and Parkinson's disease. *Neuroscience Letters*, **2009**, 453, 9-11	3.3	12
79	Global distribution and reduced penetrance: Lrrk2 R1441C in an Irish Parkinson's disease kindred. *Movement Disorders*, **2007**, 22, 291-2	7	12
78	Identification of the human ubiquitin specific protease 31 (USP31) gene: structure, sequence and expression analysis. *DNA Sequence*, **2004**, 15, 9-14		12
77	A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. *Movement Disorders*, **2016**, 31, 405-9	7	12
76	Pipeline to gene discovery - Analysing familial Parkinsonism in the Queensland Parkinson's Project. *Parkinsonism and Related Disorders*, **2018**, 49, 34-41	3.6	11
75	Genetic association study of synphilin-1 in idiopathic Parkinson's disease. *BMC Medical Genetics*, **2008**, 9, 19	2.1	11

74	A family with a tau P301L mutation presenting with parkinsonism. *Parkinsonism and Related Disorders*, **2002**, 9, 121-3	3.6	11
73	Conjugal parkinsonism - Clinical, pathology and genetic study. No evidence of person-to-person transmission. *Parkinsonism and Related Disorders*, **2016**, 31, 87-90	3.6	11
72	EIF4G1 gene mutations are not a common cause of Parkinson's disease in the Japanese population. *Parkinsonism and Related Disorders*, **2014**, 20, 659-61	3.6	10
71	DRD3 Ser9Gly and HS1BP3 Ala265Gly are not associated with Parkinson disease. *Neuroscience Letters*, **2009**, 461, 74-5	3.3	10
70	Unusual genotypes in the COL6A1 gene in parents of children with trisomy 21 and major congenital heart defects. *Human Genetics*, **1994**, 93, 443-6	6.3	10
69	p.Met233Val in a Complex Neurodegenerative Movement and Neuropsychiatric Disorder. *Journal of Movement Disorders*, **2018**, 11, 45-48	2.9	10
68	Parkinson's disease, genetic variability and the Faroe Islands. *Parkinsonism and Related Disorders*, **2015**, 21, 75-8	3.6	9
67	Whole-Exome Sequencing of an Exceptional Longevity Cohort. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2019**, 74, 1386-1390	6.4	9
66	PARK2 variability in Polish Parkinson's disease patients--interaction with mitochondrial haplogroups. *Parkinsonism and Related Disorders*, **2012**, 18, 520-4	3.6	9
65	Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease. *Journal of Molecular Neuroscience*, **2004**, 24, 337-42	3.3	9
64	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. *Annals of Neurology*, **2021**, 90, 76-88	9.4	9
63	Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons. *Journal of Parkinsonks Disease*, **2019**, 9, 121-139	5.3	9
62	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease. *Neurobiology of Aging*, **2021**, 97, 148.e17-148.e24	5.6	9
61	SCA2 family presenting as typical Parkinson's disease: 34 year follow up. *Parkinsonism and Related Disorders*, **2017**, 40, 69-72	3.6	8
60	Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation Carriers. *Annals of Neurology*, **2019**, 86, 324-326	9.4	8
59	Doubts about TMEM230 as a gene for parkinsonism. *Nature Genetics*, **2019**, 51, 367-368	36.3	8
58	Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous mutations and ameliorated by genetic knock-out. *Brain Communications*, **2020**, 2, fcz052	4.5	8
57	Leucine-rich repeat kinase 2 is a regulator of B cell function, affecting homeostasis, BCR signaling, IgA production, and TI antigen responses. *Journal of Neuroimmunology*, **2016**, 292, 1-8	3.5	8

56	LRRK2 variation and Parkinson's disease in African Americans. *Movement Disorders*, **2010**, 25, 1973-6	7	8
55	Calbindin-1 association and Parkinson's disease. *European Journal of Neurology*, **2010**, 17, 208-11	6	8
54	Dopamine beta-hydroxylase -1021C>T association and Parkinson's disease. *Parkinsonism and Related Disorders*, **2008**, 14, 544-7	3.6	8
53	Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. *Movement Disorders*, **2007**, 22, 389-92	7	8
52	Aprataxin (APTX) gene mutations resembling multiple system atrophy. *Parkinsonism and Related Disorders*, **2007**, 13, 139-42	3.6	8
51	Genetics of restless legs syndrome. *Parkinsonism and Related Disorders*, **2006**, 12, 1-7	3.6	8
50	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. *Genetics in Medicine*, **2014**, 16, 644-5	8.1	7
49	Analysis of PArkin Co-Regulated Gene in a Taiwanese-ethnic Chinese cohort with early-onset Parkinson's disease. *Parkinsonism and Related Disorders*, **2009**, 15, 417-21	3.6	7
48	Association of pyridoxal kinase and Parkinson disease. *Annals of Neurology*, **2010**, 67, 409-11	9.4	7
47	Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism. *Neuroscience Letters*, **2005**, 380, 257-9	3.3	7
46	Neuropathological findings in PINK1-associated Parkinson's disease. *Parkinsonism and Related Disorders*, **2020**, 78, 105-108	3.6	7
45	Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors. *Movement Disorders*, **2020**, 35, 1854-1858	7	7
44	Novel LRRK2 mutations in Parkinsonism. *Parkinsonism and Related Disorders*, **2015**, 21, 1119-21	3.6	6
43	The role of SNCA and MAPT in Parkinson disease and LRRK2 parkinsonism in the Tunisian Arab-Berber population. *European Journal of Neurology*, **2014**, 21, e91-2	6	6
42	GRN 3'UTR+78 C>T is not associated with risk for Parkinson's disease. *European Journal of Neurology*, **2009**, 16, 909-11	6	6
41	Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis. *Journal of Neural Transmission*, **2007**, 114, 327-9	4.3	6
40	Dopa-responsive dystonia presenting with prominent isolated bilateral resting leg tremor: Evidence for a role of parkin?. *Movement Disorders*, **2003**, 18, 1070-1072	7	6
39	LRRK2 gene and tremor-dominant parkinsonism. *Archives of Neurology*, **2006**, 63, 1346-7		6

38	DNAJC13 p.Asn855Ser, implicated in familial parkinsonism, alters membrane dynamics of sorting nexin 1. *Neuroscience Letters*, **2019**, 706, 114-122	3.3	5
37	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. *Neurobiology of Aging*, **2017**, 49, 217.e1-217.e4	5.6	5
36	Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease. *Parkinsonism and Related Disorders*, **2007**, 13, 386-8	3.6	5
35	The Gut-Brain Axis and Its Relation to Parkinson's Disease: A Review.. *Frontiers in Aging Neuroscience*, **2021**, 13, 782082	5.3	5
34	Clinical and genetic description of a family with a high prevalence of autosomal dominant restless legs syndrome. *Mayo Clinic Proceedings*, **2009**, 84, 134-8	6.4	5
33	Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy. *Molecular Brain*, **2019**, 12, 92	4.5	4
32	Patient-control association study of the Leucine-Rich repeat kinase 2 (LRRK2) gene in South African Parkinson's disease patients. *Movement Disorders*, **2013**, 28, 2039-40	7	4
31	Death-associated protein kinase 1 variation and Parkinson's disease. *European Journal of Neurology*, **2011**, 18, 1090-3	6	4
30	Call for participation in the neurogenetics consortium within the Human Variome Project. *Neurogenetics*, **2011**, 12, 169-73	3	4
29	Common variants in Parkinson's disease. *Movement Disorders*, **2007**, 22, 899-900	7	4
28	-associated neurodevelopmental disorder. *Journal of Medical Genetics*, **2021**, 58, 196-204	5.8	4
27	Neurobehavioral characterization of adult-onset Alexander disease: A family study. *Neurology: Clinical Practice*, **2017**, 7, 425-429	1.7	3
26	Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study. *BMC Medical Genetics*, **2012**, 13, 16	2.1	3
25	VPS35 Mutations in Parkinson Disease. *American Journal of Human Genetics*, **2011**, 89, 347	11	3
24	The ancestry of LRRK2 Gly2019Ser parkinsonism Authors' reply. *Lancet Neurology, The*, **2008**, 7, 770-771	24.1	3
23	Atypical Parkinsonism and SCA8. *Parkinsonism and Related Disorders*, **2006**, 12, 396	3.6	3
22	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. *Journal of Parkinsonks Disease*, **2021**,	5.3	3
21	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. *Brain*, **2017**, 140, e33	11.2	2

20	Parkinson disease risk variants in East Asian populations. *Nature Reviews Neurology*, **2020**, 16, 461-462	15	2
19	Family with primary periodic paralysis and a mutation in MCM3AP, a gene implicated in mRNA transport. *Muscle and Nerve*, **2019**, 60, 311-314	3.4	2
18	Two large Polish kindreds with levodopa-responsive Parkinsonism not linked to known Parkinsonian genes and loci. *Parkinsonism and Related Disorders*, **2003**, 9, 193-200	3.6	2
17	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.. *Movement Disorders*, **2022**,	7	2
16	TMEM230 is not a gene for Parkinson□ disease		2
15	Diagnostic Yield and Treatment Impact of Targeted Exome Sequencing in Early-onset Epilepsy		2
14	Double homozygous mutations (R275W and M432V) in the ParkinGene associated with late-onset Parkinson's disease. *Movement Disorders*, **2016**, 31, 423-5	7	2
13	Conjugal parkinsonism is coincidental. *Parkinsonism and Related Disorders*, **2016**, 33, 149-150	3.6	2
12	Reply: GIGYF2 variants are not associated with Parkinson's disease in Italy. *Movement Disorders*, **2009**, 24, 1868-1869	7	1
11	GCH1 expression in human cerebellum from healthy individuals is not gender dependent. *Neuroscience Letters*, **2009**, 462, 73-5	3.3	1
10	The genetics and molecular biology of alpha-synuclein. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2008**, 89, 313-9	3	1
9	Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. *Journal of Neural Transmission*, **2005**, 112, 1487-502	4.3	1
8	Hunting for Familial Parkinson's Disease Mutations in the Post Genome Era. *Genes*, **2021**, 12,	4.2	1
7	Genetics of Parkinson's Disease **2008**, 9-33		0
6	LRRK2; a dynamic regulator of cellular trafficking. *Brain Research*, **2021**, 1761, 147394	3.7	0
5	Chronic and Acute Manipulation of Cortical Glutamate Transmission Induces Structural and Synaptic Changes in Co-cultured Striatal Neurons. *Frontiers in Cellular Neuroscience*, **2021**, 15, 569031	6.1	0
4	Identification of a Novel Gene Linked to Parkin via a Bidirectional Promoter. *Annals of the New York Academy of Sciences*, **2006**, 991, 311-314	6.5	
3	LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism **2008**, 75-89		

2	Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis **2014**, 161	
1	Reply: UQCRC1 variants in Parkinson's disease: a large cohort study in Chinese mainland population. *Brain*, **2021**, 144, e55	11.2